Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- REGULATORY NEWS IN BRIEF
November 3, 2008
- JSHP President Not Ready to Consider Merger with JPA
November 3, 2008
- DSP to Embark on Joint Research with Osaka Univ. in Neuropsychiatry
November 3, 2008
- Number of Pharmacies Totals 52,539
November 3, 2008
- Takeda Discontinues Development of Prostate Cancer Vaccine GVAX
November 3, 2008
- BI to Enter Market for Antidiabetics with BI 1356: Dr Barner
November 3, 2008
- Banyu to Close Tsukuba Research Institute
November 3, 2008
- Stop Press／Falls in Market Prices Hit Business of Major Wholesalers
November 3, 2008
- 5TH DIA Workshop
November 3, 2008
- Ono Obtains License to SC MNTX in Japan from Progenics
November 3, 2008
- Kitasato Univ. Supports PIII Trial for Uterocervical Cancer in Asia
November 3, 2008
- Policies for Development of Biosimilars Drafted by Korosho
November 3, 2008
- Daiichi Sankyo Acquires 52.5% of Ranbaxy Shares
November 3, 2008
- SURVEY／Number of Bioventures Is Declining: JBA Survey
November 3, 2008
- Smaller Firms Should Also Be Able to Benefit from FPMAJ-Proposed NHI Pricing System: Mr Nagano
November 3, 2008
- JGA to Work to Make More Data Available for Promoting Generics
November 3, 2008
- Ryukaikon to Meet on Nov. 5 for the First Time One Year after Issuing Emergency Calls
November 3, 2008
- Criteria for Premium for Dispensing Generics Must Be Discussed by Chuikyo Members
November 3, 2008
- BUSINESS NEWS IN BRIEF
November 3, 2008
- Calls by MRs Most Important Factor when Pharmacies Choose Generics
November 3, 2008
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…